| 1663 |
National Cancer Institute |
Html |
en |
Childhood Astrocytomas Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of childhood astrocytomas. |
| cancer treatment | 0.624127 |
| new cancer cells | 0.50571 |
| high-grade astrocytoma | 0.568902 |
| star-shaped brain cells | 0.50361 |
| metastatic brain tumors | 0.515525 |
| type | 0.567046 |
| tuberous sclerosis | 0.508341 |
| chemotherapy | 0.51254 |
| proton beam radiation | 0.504515 |
| PDQ cancer information | 0.568694 |
| clinical trial search | 0.544652 |
| brain tumors | 0.664824 |
| children | 0.509721 |
| new blood vessels | 0.577461 |
| dead tumor cells | 0.517027 |
| clinical trials | 0.906249 |
| cancer information summary | 0.537035 |
| clinical trial | 0.760659 |
| stem cell transplant | 0.512502 |
| treatment clinical trial | 0.503103 |
| radiation therapy | 0.993729 |
| Treatment Editorial Board | 0.497213 |
| beam radiation therapy | 0.519746 |
| subependymal giant cell | 0.530817 |
|
| treatment | 0.904348 |
| general information | 0.532617 |
| cancer cells | 0.898737 |
| conformal radiation therapy | 0.568043 |
| intensity-modulated radiation therapy | 0.52166 |
| specific cancer cells | 0.501338 |
| stereotactic radiation therapy | 0.544315 |
| childhood high-grade astrocytoma | 0.500502 |
| astrocytoma | 0.619975 |
| low-grade astrocytoma | 0.590271 |
| treatment clinical trials | 0.531572 |
| National Cancer Institute | 0.535683 |
| spinal cord | 0.789593 |
| effects cancer treatment | 0.512031 |
| new treatment | 0.578461 |
| external radiation therapy | 0.577741 |
| brain | 0.729014 |
| childhood astrocytoma | 0.499108 |
| cancer clinical trials | 0.564469 |
| checks tumor tissue | 0.501876 |
| tumor | 0.802924 |
| cancer | 0.956922 |
| information | 0.571652 |
| childhood low-grade astrocytoma | 0.521596 |
|
CLICK HERE |
| 1730 |
National Cancer Institute |
Html |
en |
Blood-Forming Stem Cell Transplants |
A fact sheet that explains the step-by-step procedures of two types of transplantations used with high-dose chemotherapy, including their risks and benefits. |
| red blood cells | 0.400014 |
| cancer treatment | 0.26536 |
| cord blood | 0.408194 |
| public cord blood | 0.298389 |
| bone marrow cells | 0.392639 |
| cord blood bank | 0.313292 |
| embryonic stem cells | 0.414015 |
| cord stem cells | 0.382315 |
| healthy cells | 0.309763 |
| bone marrow donation | 0.293131 |
| white blood cells | 0.53145 |
| transplanted stem cells | 0.39836 |
| HLA-matched stem cells | 0.374986 |
| clinical trials | 0.346744 |
| healthy stem cells | 0.372316 |
| stem cells | 0.95315 |
| stem cell transplant | 0.291072 |
| multiple myeloma | 0.26697 |
| Bone marrow aspiration | 0.292859 |
| cord blood banks | 0.343333 |
| immature cells | 0.319355 |
| HLA antigens | 0.259199 |
| appropriate unrelated donor | 0.262231 |
| radiation therapy | 0.329306 |
| transplantation | 0.292216 |
|
| blood-forming stem cells | 0.415789 |
| immature nerve cells | 0.328089 |
| Large volunteer donor | 0.262362 |
| new blood cells | 0.334223 |
| blood stem cell | 0.339528 |
| cancer cells | 0.404042 |
| special blood test | 0.260646 |
| peripheral blood stem | 0.362146 |
| anticancer drugs | 0.263549 |
| donor | 0.356002 |
| PBSCT | 0.299118 |
| patient | 0.341681 |
| marrow’s ability | 0.258871 |
| blood stem cells | 0.413585 |
| healthy bone marrow | 0.302284 |
| umbilical cord blood | 0.366965 |
| umbilical cord | 0.389737 |
| harvested cells | 0.30119 |
| commercial cord blood | 0.270418 |
| Marrow Donor Program® | 0.288844 |
| BMT | 0.322432 |
| bone marrow | 0.850438 |
| autologous transplant | 0.272369 |
| hematopoietic stem cells | 0.478378 |
|
CLICK HERE |
| 1842 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de endometrio (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de endometrio. |
| Endometrial Cancer Group | 0.318951 |
| Obstet Gynecol | 0.338539 |
| papillary serous carcinoma | 0.328892 |
| uterine papillary serous | 0.337487 |
| positive peritoneal cytology | 0.310059 |
| with low-risk stage | 0.308461 |
| endometrial carcinoma | 0.512882 |
| prognostic factors | 0.307871 |
| Radiat Oncol Biol | 0.365388 |
| surgical staging | 0.309654 |
| laparoscopy versus laparotomy | 0.308759 |
| oncology group study | 0.336362 |
| endometrio estadio | 0.314607 |
| prognostic significance | 0.310042 |
| Natl Cancer Inst | 0.338736 |
| Gynecologic Oncology Group | 0.394499 |
| cancer staging | 0.313796 |
| Gynecol Oncol | 0.593302 |
| patients with | 0.367043 |
| radiation therapy | 0.313526 |
| Braquiterapia vaginal posoperatoria | 0.30677 |
| endometrial cancer | 0.978339 |
| peritoneal cytology | 0.312286 |
| stage-1 endometrial carcinoma | 0.31493 |
| cases with carcinoma | 0.307561 |
|
| Operative Radiation Therapy | 0.306859 |
| Lancet Oncol | 0.306692 |
| with endometrial carcinoma | 0.344016 |
| Danish Endometrial Cancer | 0.332392 |
| estadio iv | 0.31911 |
| estadio ii | 0.371493 |
| with surgical stage | 0.316597 |
| Cancer Staging Manual | 0.308545 |
| Féderation Internationale | 0.308609 |
| endometrial carcinoma only | 0.316396 |
| Endometrial Cancer Study | 0.319041 |
| stage i-ii papillary | 0.306581 |
| endometrial carcinoma among | 0.316625 |
| Clin Oncol | 0.320098 |
| surgical stage | 0.327711 |
| Oncol Biol Phys | 0.368458 |
| Cancer Genome Atlas | 0.314564 |
| estadio iii | 0.309959 |
| clinical stage | 0.315784 |
| cuello uterino | 0.329408 |
| Gynecol Cancer | 0.309855 |
| vaginal brachytherapy | 0.308102 |
| treated with | 0.309769 |
| with or without | 0.308543 |
|
CLICK HERE |
| 1888 |
National Cancer Institute |
Html |
es |
Tratamiento del linfoma de Hodgkin en adultos (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del linfoma de Hodgkin en adultos. |
| siguientes procedimientos | 0.457132 |
| células madre | 0.773484 |
| sedimentación globular vsg | 0.343223 |
| estadio iv | 0.386067 |
| siguientes elementos | 0.335371 |
| sudores nocturnos | 0.52867 |
| Elabora glóbulos | 0.342317 |
| siguientes afecciones | 0.326701 |
| siguientes especialistas | 0.324883 |
| siguientes tipos | 0.334479 |
| área cercanos.ampliar linfoma | 0.414688 |
| rayos x | 0.318853 |
| Hodgkin Lymphoma | 0.444389 |
| abdomen).ampliar linfoma | 0.405698 |
| enlace drugs approved | 0.376199 |
| largo plazo | 0.313634 |
| malformaciones congénitas | 0.344911 |
| escáner tep | 0.32264 |
| ondas sonoras | 0.318768 |
| estadio ie | 0.448154 |
| efectos tardÃos | 0.386184 |
| cáncer.ampliar aspiración | 0.320544 |
|
| quimioterapia sistémica | 0.399855 |
| National Cancer Institute | 0.315084 |
| siguientes riesgos | 0.314848 |
| Instituto Nacional | 0.326237 |
| PDQ Tratamiento | 0.422426 |
| estadio iie | 0.390253 |
| lÃquido incoloro | 0.32327 |
| Herpes zóster | 0.316049 |
| estadio iiie | 0.444346 |
| siguientes problemas | 0.333894 |
| estadio e | 0.345757 |
| siguientes factores | 0.326864 |
| Physician Data Query | 0.353006 |
| siguientes subtipos | 0.336371 |
| siguientes sitios | 0.33013 |
| Leucemia mielógena aguda | 0.327537 |
| hodgkin clásico.ampliar célula | 0.434672 |
| estadio iiis | 0.943901 |
| células formadoras | 0.331979 |
| almacena glóbulos | 0.343421 |
| siguientes sumarios | 0.346893 |
| siguientes pruebas | 0.333482 |
|
CLICK HERE |
| 1929 |
National Cancer Institute |
Html |
es |
Tratamiento del carcinoma de sitio primario desconocido (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer metastásico que se diseminó desde un sitio primario desconocido. |
| PDQ Tratamiento | 0.503744 |
| siguientes procedimientos | 0.523984 |
| alta potencia | 0.503524 |
| siguientes elementos | 0.505673 |
| siguientes aspectos | 0.504431 |
| Physician Data Query | 0.507109 |
| coriónica humana beta | 0.506354 |
| radioterapia externa causa | 0.507986 |
| tumor primario oculto.Ampliar | 0.520296 |
| siguientes razones | 0.505928 |
| siguientes tipos | 0.504856 |
|
| vÃa oral | 0.502538 |
| rayos x | 0.503516 |
| sitio primario desconocido | 0.964151 |
| Sudores nocturnos | 0.504661 |
| cuáles pruebas | 0.503677 |
| numerosos ensayos | 0.506292 |
| National Cancer Institute | 0.501623 |
| siguientes riesgos | 0.501356 |
| células cancerosas ayuda | 0.516934 |
| Instituto Nacional | 0.503286 |
|
CLICK HERE |
| 2003 |
National Cancer Institute |
Html |
es |
Tratamiento de los tumores de estroma gastrointestinal (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de los tumores de estroma gastrointestinal |
| Corless CL | 0.538141 |
| Gastric stromal sarcoma | 0.50605 |
| stromal tumors irrespective | 0.50378 |
| Gastrointestinal pacemaker | 0.510002 |
| cases with | 0.505031 |
| Demetri GD | 0.510561 |
| antÃgeno cd117 | 0.5043 |
| stromal tumors but | 0.503793 |
| Sin embargo | 0.508884 |
| KIT-negative gastrointestinal | 0.505275 |
| gastrointestinal stromal sarcomas | 0.507782 |
| gen kit | 0.50569 |
| Cancer Res | 0.504191 |
| sclerosing stromal tumors | 0.504057 |
| receptor kit | 0.508691 |
| with mutational analysis | 0.504267 |
| stromal tumor patient | 0.504863 |
| Multiple gastrointestinal | 0.505317 |
| before imatinib with | 0.505687 |
| PDGFRA activating mutations | 0.504562 |
| Oncol Rep | 0.503948 |
| nervioso autónomo gastrointestinal | 0.506079 |
| interstitial cells | 0.505694 |
| TEGI primario recién | 0.504948 |
| new cases with | 0.504631 |
|
| verdadero tegi | 0.504221 |
| stromal tumor occurs | 0.504698 |
| gastric stromal tumours | 0.506473 |
| microscopic gastrointestinal | 0.505987 |
| gastrointestinal tract | 0.505493 |
| gastrointestinal stromal tumors | 0.979159 |
| Surg Pathol | 0.538619 |
| Duensing A | 0.505663 |
| tumors have unique | 0.505149 |
| molecular genetic study | 0.50922 |
| Cancer Staging Manual | 0.525628 |
| tirosina cinasa kit | 0.507752 |
| tirosina cinasa | 0.607449 |
| proteÃna cinasa | 0.508725 |
| Heinrich MC | 0.512562 |
| carney triad | 0.506455 |
| gastrointestinal stromal tumours | 0.529292 |
| with long-term follow-up | 0.503857 |
| stromal sarcoma | 0.507115 |
| metastatic gastrointestinal | 0.505468 |
| NF1-associated gastrointestinal | 0.509992 |
| ANNUAL REVIEWS | 0.505692 |
| pacemaker cell tumor | 0.506911 |
| AJCC Cancer Staging | 0.518324 |
|
CLICK HERE |
| 2014 |
National Cancer Institute |
Html |
es |
Aspectos generales de los exámenes de detección del cáncer (PDQ®)–Versión para profesionales de salud |
Información sobre la medición de la eficacia de las pruebas de detección del cáncer y la evaluación de la solidez de las pruebas obtenidas en estudios de investigación de detección del cáncer. |
| Does screening | 0.616458 |
| importancia clÃnica | 0.620073 |
| muertes prematuras | 0.612815 |
| American Cancer Society | 0.649437 |
| Woods WG | 0.609081 |
| shared decision-making | 0.610684 |
| únicos exámenes | 0.617228 |
| Malmo mammographic screening | 0.618339 |
| case-control studies | 0.618658 |
| Instituto Nacional | 0.618095 |
| SEER Program | 0.61206 |
| examen tisular | 0.612004 |
| patient decision aids | 0.642735 |
| Estados Unidos | 0.671925 |
| Clin Epidemiol | 0.61257 |
| Natl Cancer Inst | 0.655145 |
| screening with | 0.61747 |
| screening efficacy | 0.629033 |
| cancer screening | 0.803421 |
| Kramer BS | 0.609339 |
| estadio iv | 0.624173 |
| Cancer Intervention | 0.613844 |
| End Results | 0.611945 |
| Evaluating new screening | 0.618163 |
| voluntarios sanos | 0.610696 |
|
| Decision Aid Standards | 0.609164 |
| sobrediagnóstico resultante | 0.608646 |
| diagnosed with | 0.611303 |
| decision aid | 0.652528 |
| Cancer Facts | 0.614043 |
| Day NE | 0.608989 |
| datos probatorios indirectos | 0.611287 |
| evaluating neuroblastoma screening | 0.619704 |
| Welch HG | 0.609007 |
| mammography screening | 0.616883 |
| cancer screening strategies | 0.649219 |
| Intern Med | 0.611038 |
| breast cancer screening | 0.675789 |
| Clin Oncol | 0.611547 |
| Cancer screening among | 0.630365 |
| systematic review | 0.61189 |
| cáncer surveillance | 0.636085 |
| Mass screening | 0.616536 |
| cuello uterino | 0.611009 |
| Neuroblastoma Screening Project | 0.622021 |
| datos probatorios | 0.981275 |
| Black WC | 0.609219 |
| mejores desenlaces | 0.609922 |
| Cancer Screening Trial | 0.636288 |
|
CLICK HERE |
| 15637 |
National Cancer Institute |
Html |
null |
Research Funding Mechanisms |
The NCI uses grants, cooperative agreements, and contracts to help stimulate and fund cancer research. |
|
|
CLICK HERE |
| 16257 |
National Cancer Institute |
Html |
es |
Prevención |
La investigación del NCI de prevención va desde identificación de factores ambientales y de estilos de vida que influyen en el riesgo de cáncer hasta la biología de la formación del cáncer y la evaluación para diseminar intervenciones de prevención. |
| próxima generación | 0.432035 |
| Mejor reducción | 0.436692 |
| Investigación Nacional Colaborativa | 0.455747 |
| Investigación Oncológica | 0.43883 |
| Nuevos planteamientos | 0.440499 |
| investigación sustancias | 0.43567 |
| Estudio Vida Familiar | 0.45233 |
| Estados Unidos | 0.908876 |
| numerosos factores | 0.443836 |
| cabo estudios | 0.446295 |
| Cáncer apoya programas | 0.610288 |
|
| cánceres más | 0.43473 |
| numerosos estudios | 0.443241 |
| posibles terapias | 0.437443 |
| Pre-Cancer Atlas | 0.437082 |
| el uso | 0.430938 |
| inmensa complejidad | 0.437794 |
| amplio rango | 0.43275 |
| prevención del cáncer del nci | 0.509541 |
| creación de vacunas | 0.467866 |
| prueba formas | 0.434098 |
| Estados Unidos gastarán | 0.466237 |
|
CLICK HERE |
| 17189 |
National Cancer Institute |
Html |
en |
Sexual Health Issues in Women with Cancer |
Cancer treatments such as chemotherapy, hormone therapy, and radiation may cause sexual problems in women. Conditions may include vaginal dryness, vaginal stenosis, and vaginal atrophy. Learn how to manage and treat these sexual problems. |
| cancer treatment | 0.51645 |
| vaginal tissue | 0.532819 |
| primary ovarian insufficiency | 0.548774 |
| endocrine therapy | 0.478386 |
| health care team | 0.776749 |
| sexual life | 0.612375 |
| support group | 0.540233 |
| gynecologic cancers | 0.477639 |
| social worker | 0.530013 |
| pelvic muscles | 0.474973 |
| sexual activity | 0.559668 |
| sexual health | 0.668647 |
| sexual intercourse | 0.555683 |
| low estrogen levels | 0.65848 |
| hair loss | 0.473268 |
| physical changes | 0.478751 |
| birth control | 0.564552 |
| Fertility Issues | 0.55759 |
| effects | 0.479305 |
| sexual problems | 0.5327 |
| hot flashes | 0.548172 |
| radiation therapy | 0.542011 |
| long term | 0.480571 |
| valuable suggestions | 0.473342 |
| vaginal dryness | 0.649951 |
|
| vaginal gels | 0.527917 |
| problems | 0.541005 |
| women | 0.505517 |
| cancer treatments | 0.472282 |
| treatment | 0.973526 |
| sex life | 0.471664 |
| personal health factors | 0.547006 |
| vaginal secretions | 0.525892 |
| cancer-related support services | 0.536181 |
| changes | 0.511207 |
| Vaginal stenosis | 0.532538 |
| vaginal wall | 0.531486 |
| vaginal atrophy | 0.531565 |
| hormone therapy | 0.536753 |
| sexual changes | 0.501579 |
| bladder retention | 0.472634 |
| shorter vagina | 0.48061 |
| sexual health expert | 0.553722 |
| support groups | 0.47572 |
| Breast Cancer | 0.475837 |
| doctor | 0.494029 |
| bowel function | 0.475187 |
| national organizations | 0.470856 |
| time | 0.509374 |
|
CLICK HERE |